SCHEMBL19971934

SCHEMBL19971934

CC(NC(=O)C(CCCNC(=O)OC(C)(C)C)NC(=O)C(N)CCCNC(=O)OC(C)(C)C)C(=O)NC(CCCNC(=O)OC(C)(C)C)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.53
GAA P10253 1/20 0.53
KMT2A Q03164 1/20 0.53
MMP1 P03956 1/20 0.42
MMP3 P08254 1/20 0.42
MMP9 P14780 1/20 0.42
CTSS P25774 2/20 0.42
CTSK P43235 2/20 0.42
CA1 P00915 3/20 0.41
CA2 P00918 3/20 0.41
NOD1 Q9Y239 3/20 0.41
TDP1 Q9NUW8 2/20 0.40
NRP1 O14786 2/20 0.40
CAPN1 P07384 1/20 0.39
MAOA P21397 1/20 0.39
MAOB P27338 1/20 0.39
MAPT P10636 1/20 0.38
NPY4R P50391 3/20 0.38
NPY1R P25929 2/20 0.38
NPY2R P49146 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30340151 0.94 MEN1 (0.51) MEN1GAAKMT2ACTSSCTSK
SCHEMBL31347339 0.93 MEN1 (0.45) MEN1GAAKMT2ACTSSCTSK
SCHEMBL13254145 0.92 MEN1 (0.49) MEN1GAAKMT2AMMP1MMP3
SCHEMBL14645121 0.92 MEN1 (0.49) MEN1GAAKMT2AMMP1MMP3
SCHEMBL30532183 0.92 MEN1 (0.53) MEN1GAAKMT2AMMP1MMP3
SCHEMBL31347317 0.90 MEN1 (0.47) MEN1GAAKMT2ACA1CA2
SCHEMBL30898863 0.89 MEN1 (0.56) MEN1GAAKMT2AMMP1MMP3
SCHEMBL19971937 0.87 MEN1 (0.48) MEN1GAAKMT2AMMP1MMP3
SCHEMBL19971936 0.87 MEN1 (0.48) MEN1GAAKMT2AMMP1MMP3
SCHEMBL30565196 0.86 MEN1 (0.53) MEN1GAAKMT2AMMP1MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10858389-B2 Solution phase method for preparing etelcalcetide AMGEN INC. (US) 2020-12-08 US disclosed
EP-3274360-B1 SOLUTION PHASE METHOD FOR PREPARING ETELCALCETIDE AMGEN INC (US) 2020-05-06 EP disclosed
US-20180079777-A1 SOLUTION PHASE METHOD FOR PREPARING ETELCALCETIDE AMGEN INC. 2018-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10858389-B2 Solution phase method for preparing etelcalcetide PTH1R, CALCR, SOST MEN1 697/4885GAA 2503/4885KMT2A 4698/4885
US-20180079777-A1 SOLUTION PHASE METHOD FOR PREPARING ETELCALCETIDE PTH1R, CALCR, SOST MEN1 697/4885GAA 2503/4885KMT2A 4698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.